{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:41:06Z","timestamp":1774658466445,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1038\/sj.bjc.6602098","type":"journal-article","created":{"date-parts":[[2004,9,14]],"date-time":"2004-09-14T10:16:40Z","timestamp":1095157000000},"page":"1066-1073","source":"Crossref","is-referenced-by-count":19,"title":["Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line"],"prefix":"10.1038","volume":"91","author":[{"given":"R","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Tari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Jean-Claude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,9,7]]},"reference":[{"key":"BF6602098_CR1","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/bjc.1993.241","volume":"67","author":"JC Baer","year":"1993","unstructured":"Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP (1993) Depletion of O-6-alkylguanine-DNA alkyltransferase correlates with potentiation of Temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67: 1299\u20131302","journal-title":"Br J Cancer"},{"key":"BF6602098_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1039\/p19870000665","volume":"1","author":"GU Baig","year":"1987","unstructured":"Baig GU, Stevens MFG (1987) Antitumor imidazotetrazines. Part 12. Reactions of mitozolomide and its 3-alkyl congeners with oxygen, nitrogen, halogen, and carbon nucleophiles. J Chem Soc Perkin Trans 1: 665\u2013667","journal-title":"J Chem Soc Perkin Trans"},{"key":"BF6602098_CR3","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1021\/jm030423m","volume":"46","author":"R Banerjee","year":"2003","unstructured":"Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ (2003) Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept. J Med Chem 46: 5546\u20135551","journal-title":"J Med Chem"},{"key":"BF6602098_CR4","first-page":"119","volume":"62","author":"JW Bodell","year":"1985","unstructured":"Bodell JW, Aida T, Berger MS, Rosenblum ML (1985) Repair of O6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas. Environ Health Perspect 62: 119\u2013126","journal-title":"Environ Health Perspect"},{"key":"BF6602098_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1124\/jpet.102.039099","volume":"303","author":"F Brahimi","year":"2002","unstructured":"Brahimi F, Matheson S, McNamee J, Tari A, Jean-Claude BJ (2002) Inhibition of epidermal growth factor receptor-mediated signaling by \u2018combi-triazene\u2019 BJ2000, a new probe for the combi-targeting postulates. J Pharmacol Exp Ther 303: 238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6602098_CR6","first-page":"5464","volume":"60","author":"Y Cai","year":"2000","unstructured":"Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME (2000) Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity in chinese hamster ovary cells expressing wildtype and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res 60: 5464\u20135469","journal-title":"Cancer Res"},{"key":"BF6602098_CR7","first-page":"27","volume":"1","author":"LM Cameron","year":"1985","unstructured":"Cameron LM, LaFrance RJ, Hemens CM, Vaughan K, Rajaraman R, Chubb DC, Goddard PM (1985) Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC. Anti-Cancer Drug Des 1: 27\u201336","journal-title":"Anti-Cancer Drug Des"},{"key":"BF6602098_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1006\/bbrc.2000.3731","volume":"277","author":"X Chen","year":"2000","unstructured":"Chen X, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells coexpressing erb2 with EGF receptor or erb3. Biochem Biophys Res Commun 277: 757\u2013763","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6602098_CR9","first-page":"909","volume":"5","author":"F Ciardiello","year":"1999","unstructured":"Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C2251. Clin Cancer Res 5: 909\u2013916","journal-title":"Clin Cancer Res"},{"key":"BF6602098_CR10","first-page":"2053","volume":"6","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G, De Placido S, Bianco AR, Tortora G (2001a) Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 6: 2053\u20132063","journal-title":"Clin Cancer Res"},{"key":"BF6602098_CR11","first-page":"2958","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello F, Tortora G (2001b) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958\u20132970","journal-title":"Clin Cancer Res"},{"key":"BF6602098_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0140-6736(03)13810-X","volume":"362","author":"JE Dancey","year":"2003","unstructured":"Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor \u2013 are we missing the mark? Lancet 362: 62\u201364","journal-title":"Lancet"},{"key":"BF6602098_CR13","doi-asserted-by":"publisher","first-page":"12022","DOI":"10.1073\/pnas.95.20.12022","volume":"95","author":"DW Fry","year":"1998","unstructured":"Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022\u201312027","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6602098_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/carcin\/7.2.259","volume":"2","author":"NW Gibson","year":"1986","unstructured":"Gibson NW, Hartley JA, LaFrance RJ, Vaughan K (1986) Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer\u2212 phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis 2: 259\u2013265","journal-title":"Carcinogenesis"},{"key":"BF6602098_CR15","first-page":"3496","volume":"8","author":"AB Heimberger","year":"2002","unstructured":"Heimberger AB, Learn CA, Archer GE, McLendon RE, Chwening TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2002) Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3496\u20133502","journal-title":"Clin Cancer Res"},{"key":"BF6602098_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1139\/v84-125","volume":"62","author":"CM Hemens","year":"1984","unstructured":"Hemens CM, Manning HW, Vaughan K, LaFrance RJ, Tang Y (1984) Open-chain nitrogen compounds. Part V. Hydroxymethyltriazenes: synthesis of some new alkyl homologues of the anti-tumour 3-methyl-3-hydroxymethyltriazenes and preparation of the derived acetoxymethyl-, benzoyloxymethyl-, and methoxymethyltriazenes. Can J Chem 62: 741\u2013748","journal-title":"Can J Chem"},{"key":"BF6602098_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1039\/p29860000011","volume":"2","author":"CM Hemens","year":"1986","unstructured":"Hemens CM, Vaughan K (1986) Kinetic study of the solvolysis reactions of 1-aryl-3-acetoxymethyl-3-alkyltriazenes: evidence for iminium ion intermediates and the SN1 mechanism. J Chem Soc Perkin Trans 2: 11\u201315","journal-title":"J Chem Soc Perkin Trans"},{"key":"BF6602098_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1039\/P29870001503","volume":"2","author":"J Iley","year":"1987","unstructured":"Iley J (1987) Triazene drug metabolites. Part 4. Kinetics and mechanism of the decomposition of 1-aryl-3-benzoyloxymethyl-3-methyltriazenes in mixed aqueous\u2013organic solvents. J Chem Soc Perkin Trans 2: 1503\u20131508","journal-title":"J Chem Soc Perkin Trans"},{"key":"BF6602098_CR19","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1039\/p19910003241","volume":"12","author":"J Iley","year":"1991","unstructured":"Iley J, Moreira R, Rosa E (1991) Triazene drug metabolites. Part 11. Synthesis of S-cysteinyl and related derivatives of N-hydroxymethyltriazenes. J Chem Soc Perkin Trans 1 12: 3241\u20133244","journal-title":"J Chem Soc Perkin Trans 1"},{"key":"BF6602098_CR20","first-page":"515","volume":"12","author":"C Lanzi","year":"1997","unstructured":"Lanzi C, Pensa T, Cassinis M, Corti C, Gambetta AR, Pratesi G, Menta E, Ardini E, Zagon IS (1997) A cell and mechanism-based approach for the selection of EGF receptor inhibitors. Anti-cancer Drug Des 12: 515\u2013524","journal-title":"Anti-cancer Drug Des"},{"key":"BF6602098_CR21","first-page":"619","volume":"51","author":"SM Lee","year":"1991","unstructured":"Lee SM, Thatcher N, Margison GP (1991) O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following Dacarbazine and Fotemustine. Cancer Res 51: 619\u2013623","journal-title":"Cancer Res"},{"key":"BF6602098_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.bjc.6600103","volume":"86","author":"N Magn\u00e9","year":"2002","unstructured":"Magn\u00e9 N, Fischel JL, Dubreuil A, Formento P, Marci\u00e9 S, Lagrange JL, Milano G (2002) Sequence-dependent effects of ZD 1839 (\u2018Iressa\u2019) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819\u2013827","journal-title":"Br J Cancer"},{"key":"BF6602098_CR23","first-page":"832","volume":"296","author":"S Matheson","year":"2001","unstructured":"Matheson S, McNamee J, Jean-Claude BJ (2001) Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharmacol Exp Ther 296: 832\u2013840","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6602098_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00280-002-0525-4","volume":"51","author":"SL Matheson","year":"2003","unstructured":"Matheson SL, McNamee J, Jean-Claude BJ (2003a) Differential responses of EGFR\u2212\/\u2212AGT-expressing cells to the \u2018combi-triazene\u2019 SMA41. Cancer Chemother Pharmacol 51: 11\u201320","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6602098_CR25","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.bcp.2003.10.035","volume":"67","author":"SL Matheson","year":"2004","unstructured":"Matheson SL, McNamee JP, Jean-Claude BJ (2004a) Internalization of the binary EGFR\/DNA-targeting \u2018combi-triazene\u2019 SMA41. Biochem Pharmacol 67: 1131\u20131138","journal-title":"Biochem Pharmacol"},{"key":"BF6602098_CR26","doi-asserted-by":"crossref","unstructured":"Matheson SL, McNamee JP, Wang T, Aloui-Jamali MA, Tari A, Jean-Claude BJ (2004b) The Combi-Targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antiproliferative effects in vivo. (in preparation)","DOI":"10.1124\/jpet.104.071977"},{"key":"BF6602098_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/jlcr.713","volume":"46","author":"SL Matheson","year":"2003","unstructured":"Matheson SL, Mzengeza S, Jean-Claude BJ (2003b) Synthesis of 1-[4-(m-tolyl)amino-6-quinazolinyl]-3-[14C]-methyl triazene: a radiolabeled probe for the combi-targeting concept. J Label Comp Radiopharm 46: 729\u2013735","journal-title":"J Label Comp Radiopharm"},{"key":"BF6602098_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1383-5718(00)00004-8","volume":"466","author":"JP McNamee","year":"2000","unstructured":"McNamee JP, Mclean JR, Ferrrotto CL, Bellier PV (2000) Comet assay: rapid processing of multiple samples. Mutat Res 466: 63\u201369","journal-title":"Mutat Res"},{"key":"BF6602098_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0301-2115(96)02630-9","volume":"71","author":"H Meden","year":"1997","unstructured":"Meden H, Kuhn W (1997) Overexpression of the oncogene c-erbB-2 (HER2,neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 71: 173\u2013179","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BF6602098_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1139\/v92-024","volume":"70","author":"MP Merrin","year":"1992","unstructured":"Merrin MP, Hooper DL (1992) Open-chain nitrogen compounds. Part XIV. Synthesis of 1-aryl-2-aryloxymethyl-3-methyltriazenes and 1-aryl-3-(hydroxyaryl)methyl-3-methyltriazenes. Can J Chem 70: 144\u2013150","journal-title":"Can J Chem"},{"key":"BF6602098_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF00685877","volume":"32","author":"RB Mitchel","year":"1993","unstructured":"Mitchel RB, Dolan ME (1993) Effect of Temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32: 59\u201363","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6602098_CR32","first-page":"277","volume":"4","author":"H Modjtahedi","year":"1994","unstructured":"Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 4: 277\u2013296","journal-title":"Int J Oncol"},{"key":"BF6602098_CR33","first-page":"8887","volume":"61","author":"SL Moulder","year":"2001","unstructured":"Moulder SL, Yakes FM, Muthswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits Her2\/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887\u20138895","journal-title":"Cancer Res"},{"key":"BF6602098_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0079-6603(08)60879-X","volume":"51","author":"AE Pegg","year":"1995","unstructured":"Pegg AE, Dolan ME, Moschel RC (1995) Structure, function and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucl Acid Res Mol Biol 51: 167\u2013223","journal-title":"Prog Nucl Acid Res Mol Biol"},{"key":"BF6602098_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pros.10353","volume":"59","author":"Q Qiu","year":"2004","unstructured":"Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ (2004) Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 59: 13\u201321","journal-title":"Prostate"},{"key":"BF6602098_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-002-0524-5","volume":"51","author":"Q Qiu","year":"2003","unstructured":"Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ (2003) The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 51: 1\u201310","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6602098_CR37","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1021\/jm030142e","volume":"46","author":"Z Rachid","year":"2003","unstructured":"Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ (2003) The combi-targeting concept: chemical dissection of the dual targeting properties of a series of \u2018combi-triazenes\u2019. J Med Chem 46: 4313\u20134321","journal-title":"J Med Chem"},{"key":"BF6602098_CR38","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislava A, Swaisland H, Rowinski EK (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid malignant tumors: results of a phase 1 trial. J Clin Oncol 20: 2240\u20132250","journal-title":"J Clin Oncol"},{"key":"BF6602098_CR39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1021\/jm9806603","volume":"42","author":"JB Smaill","year":"1999","unstructured":"Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges a, Zhou HD, Showalter H, Winters TR, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore S (1999) Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 42: 1803\u20131815","journal-title":"J Med Chem"},{"key":"BF6602098_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1021\/jm990482t","volume":"43","author":"JB Smaill","year":"2000","unstructured":"Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan H, Reyner EL, Lipka L, Showalter HDH, Vincent PW, Elliott WL, Denny WA (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamide bearing additional solubilizing functions. J Med Chem 43: 1380\u20131397","journal-title":"J Med Chem"},{"key":"BF6602098_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K","volume":"86","author":"A Tari","year":"2000","unstructured":"Tari A, Lopez-Berestein G (2000) Serum predominantly activates MAPK and AKT kinases in EGFR- and ErbB2-overexpressing cells, respectively. Int J Cancer 86: 295\u2013297","journal-title":"Int J Cancer"},{"key":"BF6602098_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0006-2952(87)90351-0","volume":"36","author":"MJ Tisdale","year":"1987","unstructured":"Tisdale MJ (1987) Antitumor imidazotetrazeines. XV. Role of guanine O-6-alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36: 457\u2013462","journal-title":"Biochem Pharmacol"},{"key":"BF6602098_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF00123400","volume":"14","author":"T Turner","year":"1996","unstructured":"Turner T, Chen P, Goodly LJ, Wells A (1996) EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metast 14: 409\u2013418","journal-title":"Clin Exp Metast"},{"key":"BF6602098_CR44","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1139\/v88-391","volume":"66","author":"K Vaughan","year":"1988","unstructured":"Vaughan K, Manning HW (1988) Open chain nitrogen compounds. Part XIII. 1-Aryl-3-arylthiomethyl-3-methyltriazenes and 3-(arylazo)-1,3-thiazolidines. Can J Chem 66: 2487\u20132491","journal-title":"Can J Chem"},{"key":"BF6602098_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF00118180","volume":"13","author":"H Xie","year":"1995","unstructured":"Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A (1995) In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metast 13: 407\u2013419","journal-title":"Clin Exp Metast"},{"key":"BF6602098_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1667\/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2","volume":"159","author":"A Yacoub","year":"2003","unstructured":"Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP (2003) Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159: 439\u2013452","journal-title":"Radiat Res"},{"key":"BF6602098_CR47","first-page":"5464","volume":"60","author":"C Yingna","year":"2000","unstructured":"Yingna C, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME (2000) Effect of O6-benzylguanine on alkylating toxicity and mutagenicity in chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine alkyltransferases. Cancer Res 60: 5464\u20135469","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602098","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:12:20Z","timestamp":1684411940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["BF6602098"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602098","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}